Efficacy and Safety Of Ponatinib Following Failure Of Dasatinib In Patients (pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
Year: 2013
Type: article
Source: Blood
Authors: Andreas Hochhaus, Jorge E. Cortes, Dong-Wook Kim, Javier Pinilla-Ibarz, Philipp D le Coutre, Ronald Paquette, Charles Chuah, Franck E. Nicolini, Jane F Apperley, H. Jean Khoury, Moshe Talpaz, John F. DiPersio, Daniel J DeAngelo, Elisabetta Abruzzese, Delphine Rea, Michele Baccarani, Martin C. Müller, Carlo Gambacorti-Passerini, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D Turner, Frank G Haluska, Michael W. Deininger, Timothy P. Hughes, John M Goldman, Neil P. Shah, Hagop M. Kantarjian, François Guilhot
Institutions: Jena University Hospital, The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Moffitt Cancer Center, Charité - Universitätsmedizin Berlin, University of California, Los Angeles, Ronald Reagan UCLA Medical Center, National University of Singapore, Singapore General Hospital, Duke-NUS Medical School, Hôpital Lyon Sud, Imperial College London, Winship Cancer Institute, University of Michigan, Washington University in St. Louis, Dana-Farber Cancer Institute, University of Rome Tor Vergata, St. Eugenio Hospital, Hôpital Saint-Louis, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University Medical Centre Mannheim, Azienda Ospedaliera San Gerardo, University of Milano-Bicocca, ARIAD Pharmaceuticals (United States), University of Utah, Huntsman Cancer Institute, South Australia Pathology, South Australian Health and Medical Research Institute, The University of Adelaide, University of California, San Francisco, Inserm, Centre Hospitalier Universitaire de Poitiers
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W175647981